Media Coverage

Media Coverage

Read how Vistagen’s intention to revolutionize mental health medicine is causing a buzz in the media.

Thepharmaletter logo image
VistaGen CEO notes broad market potential of ketamine-like AV-101
Read
San Francisco Business Times logo image
Health Care Digest: A small biotech goes head first, Gilead's lower tax rate and more
Read
PharmaTimes logo image
Company focus: VistaGen
Read
DDNews1 logo image
VistaGen acquires worldwide license of phase 3-ready CNS drug
Read
FierceBiotech logo image
VistaGen nabs phase 3-ready social anxiety drug from Pherin
Read
CNBC logo image
Ketamine is emerging as a popular treatment for depression. New research suggests the drug acts like an opioid
Read
Business Insider logo image
Stanford researchers are figuring out how ketamine fights depression — and why the drug has been called 'the most important discovery in half a century'
Read
Inc. logo image
24 Simple Ideas on How to Change Your Habits and Get More Done Today
Read
The Deal
VistaGen Working on Oral Ketamine-like Compound for Depression
Read